|
|
Effects of Fasudil on Serum Levels of MMP-10, ox-LDL and GSH-Px in Patients with Acute Cerebral Infarction |
SHEN Yu-hua, RUAN Qiong-yan, YANG Qi |
Shanghai Pudong New Area People's Hospital,Shanghai 201200 |
|
|
Abstract 【Objective】 To investigate the effects of fasudil on MMP-10 (matrix metalloproteinase 10), ox-LDL (ox-LDL) and GSH-Px (glutathione peroxidase) in patients with acute cerebral infarction(ACI). 【Methods】 A total of 100 patients with ACI in our hospital were randomly divided into two groups, each group with 50 cases. Patients with conventional treatment were as the control group, while patients in the observation group received fasudil in addition to the conventional treatment. Serum index levels, neurologic impairment, life activity, clinical efficacy and safety of the two groups were compared. 【Results】 After treatment, the total effective rates for the observation group and the control group were 90% and 64%, respectively. The efficiency of the observation group was significantly higher than that of the control group; the difference was statistical significance (P<0.05). The NIHSS score in the two groups decreased significantly, and the ADL score increased significantly in the two groups as well. However, the NIHSS score in the observation group was lower than that in the control group, ADL score in the observation group was higher than that in the control group; the difference was statistical significance (P<0.05). After treatment, serum MMP-10, ox-LDL and GSH-Px levels were significantly reduced in the two groups, and the reduction level of the observation group was significantly lower than that of the control group (P<0.05). There was no adverse drug effects in the observation group showing good tolerance after treatment. 【Conclusion】 The use of fasudil on the basis of conventional treatment in the clinical treatment of ACI can reduce serum MMP-10, ox-LDL and GSH-Px levels and improve the ability of daily life. It has significant curative effect, no adverse reaction and high safety, which is worthy of clinical application.
|
Received: 10 May 2019
|
|
|
|
|
[1] 马文娟,杨佳,赵世刚.普罗布考联合阿托伐他汀对脑梗死患者血清hs-CRP、ox-LDL、MMP-9水平及颈动脉斑块的影响[J].河北医学,2017,23(4):620-623.
[2] 符再立,赵艳玲,李文纯,等.针刺与康复训练不同干预次序对脑梗死患者临床疗效及TNF-α、IL-1β的影响[J].湖南中医药大学学报,2014,34(11):57-60.
[3] 卢志勇.法舒地尔联合常规治疗对急性脑梗死患者神经及凝血功能、Hcy代谢的影响[J].海南医学院学报,2017,23(1):41-44.
[4] 宋爱霞,邱波,韩朝,等.脑梗死患者血清ox-LDL、CRP、MMP-9水平与颈动脉弹性的相关性研究[J].疑难病杂志,2015,1(12):1221-1224.
[5] 陈燕萍,田锦勇,段畅,等.急性脑梗死患者肺部感染病原菌分布及对氧化应激反应蛋白的影响研究[J].中华医院感染学杂志,2015,11(20):4600-4601.
[6] 梁秀云,李通.盐酸法舒地尔对急性脑梗死患者血清Rho激酶的影响及与血液流变学相关性[J].现代中西医结合杂志,2012,21(4):348-349.
[7] Doe C, Bentley R, Behm DJ,et al.Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities[J].J Pharmacol Exp Ther,2007,320(1):89-98.
[8] 贺新萍, 杨丽娜, 李艳霞. 不同时间窗的高压氧治疗对急性脑梗死患者疗效的影响[J].医学临床研究, 2012, 29(8):1608-1609.
[9] 马福静,刘玉平,杨凤梅.法舒地尔治疗急性脑梗死的疗效及对患者血浆C-反应蛋白的影响[J].实用临床医药杂志,2013,17(11):102.
[10] 姚万青,谢睿,储辉,等.法舒地尔治疗急性脑梗死的疗效及安全性观察[J].医学综述,2013,19(17):3243-3245.
[11] 刘新宇.基质金属蛋白酶-9、C反应蛋白及P选择素对老年急性心肌梗死患者PCI治疗后效果和预后的评价[J].岭南心血管病杂志,2017,23(4):381-383,391.
[12] 陈绚.盐酸法舒地尔治疗急性脑梗死的疗效及其对血清高敏C反应蛋白水平的影响分析[J].实用心脑肺血管病杂志,2012,20(1):8-9.
[13] Yang Weilai,Xu Yinjun,Lou Wenyuan,et al.Acute myocardial cerebral infarction as first/relapse manifestation in one acute promyelocytic leukemia patient[J].Int J Clin Exp Med,2015,8(8):14210-14213. |
|
|
|